Nurix Therapeutics price target raised to $35 from $32 at Piper Sandler

Piper Sandler raised the firm’s price target on Nurix Therapeutics (NRIX) to $35 from $32 and keeps an Overweight rating on the shares following quarterly results and pipeline update. The firm notes that after the recent Phase 1 update in chronic lymphocytic leukemia/small lymphocytic lymphoma at ASH 2025, bexobrutideg pivotal development is accelerating, as the confirmatory Phase 3 trial in second-line and later CLL/SLL for potential full approval is initiating in the first half of 2026 and the first patients were dosed in the single-arm Phase 2 in the third-line and later setting in Q4 2025 for potential accelerated approval. Piper now anticipates a bexobrutideg update in relapsed/refractory non-Hodgkin lymphoma in 2026.